AstraZeneca (AZN) Announces Several Executive Changes; Luke Miels Becomes EVP of Europe - Bloomberg

August 26, 2016 12:14 PM EDT
Get Alerts AZN Hot Sheet
Trade AZN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

AstraZeneca (NYSE: AZN) announced several key leadership changes today, according to Bloomberg, citing a company email. The following changes were made:

  • Luke Miels, who was EVP of global portfolio and product strategy, global medical affairs and corporate affairs, is now EVP for Europe region;
  • International EVP, Mark Mallon, will replace Miels;
  • Former Europe EVP, Ruud Dobber, is now EVP for the company's North American business;
  • EVP, innovative medicines and early development, Mene Pangalos, will also responsible for business development;
  • Mondher Mahjoubi will take a broader role as general manager, Oncology;

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Management Changes, Trader Talk

Add Your Comment